POEMS syndrome is defined by the presence of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes. Increasing evidence suggests that an overproduction of vascular endothelial growth factor (VEGF) plays a role in the pathophysiology of POEMS syndrome. 1 As VEGF could be a therapeutic target in this disorder, bevacizumab, an anti-VEGF monoclonal antibody has been tried. However, results are contradictory. [2] [3] [4] [5] [6] Autologous peripheral blood stem cell transplantation (APBSCT) is another promising therapy for POEMS syndrome and the efficacy of this treatment has been established in the literature. 7 A 51-year-old Japanese female presented with slowly progressing distal and symmetrical sensory and motor neuropathy, skin changes and edema in January 2002. Nerve conduction studies were performed but no responses were recordable in either the motor or sensory nerves because of severe edema and skin changes. Laboratory data revealed elevated serum IgG levels that showed a monoclonal lambda component by electrophoresis. In addition, abnormal thyroid function was observed. A CT scan showed bilateral pleural effusions, ascites, splenomegaly and a soft tissue mass over the sacrum. Biopsy of the mass disclosed atypical plasma cells. A skeletal survey was performed with no evidence of any pathological fractures. A diagnosis of POEMS syndrome was made because of the solitary plasmacytoma. On admission, her serum VEGF level was 200 pg/ml (normal o38.3 pg/ml). For measuring VEGF, a 5 ml clotted blood sample was taken on ice, centrifuged at 2000 r.p.m. for 10 min at 4 1C, and a 1.5 ml aliquot of serum was stored at À80 1C until analysis. Immunoreactive VEGF was measured using an ELISA kit (R&D systems, Minneapolis, MN, USA).
Initially, we planned to treat her with high-dose chemotherapy with APBSCT, and hematopoietic progenitor cell collection was performed priming with G-CSF alone. She was then treated with radiation therapy to the plasmacytoma, but respiratory failure worsened because of the neuropathy during irradiation and she required mechanical ventilation. After undergoing a plasmacytectomy, the neuropathy gradually improved but her poor performance status necessitated postponing the APBSCT.
In May 2006, she noted worsening of the weakness in her extremities, skin changes and edema. A CT scan again revealed massive pleural effusions and ascites. An echocardiogram showed elevated pulmonary artery systolic pressure (PASP: 76 mm Hg), which was not seen on the first admission. In spite of the administration of diuretics, the extravascular volume overload did not improve. On this admission, her serum VEGF level was increased to 469 pg/ml. Levels of the other serum cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor a (TNF-a), remained within the normal ranges. At 3 weeks after admission, treatment with oral melphalan and prednisone (MP therapy) was started, but no improvement was seen. In contrast, she newly developed oliguria with serum creatinine levels elevating from 0.9 mg/dl to 1.8 mg/dl (normal 0.4-1.0 mg/dl). At this point, namely 3 weeks after the beginning of MP therapy, her serum VEGF level rose to 3330 pg/ml. After daily intermediate dose prednisone (1 mg/ kg/day) therapy, the oliguria dramatically disappeared and the renal insufficiency resolved. An echocardiogram revealed normalization of the PASP. Prednisone then was tapered slowly but symptoms other than pulmonary hypertension (PH) and renal dysfunction did not improve. At a dose of 0.5 mg/kg/day of prednisone, the patient had a World Health Organization performance status IV. Since the progression of the polyneuropathy and edema she was bedridden. Despite the worsening of her performance status, serum VEGF levels decreased to 152 pg/ml 3 weeks after beginning treatment with steroids. We were certain that conventional therapy could no longer relieve her symptoms. She then received high-dose melphalan (200 mg/ m 2 ), followed by peripheral blood stem cell rescue with the previously cryopreserved cells. During APBSCT, there were no serious complications. Three months later, she could stand unaided and walk with some assistance. Although slight edema was still present, the ascites and pleural effusion were absent 6 months post APBSCT. With no maintenance therapy, serum VEGF levels decreased to 16 pg/ml, and she was able to perform all daily living activities by herself as of 17 months after the APBSCT. Table 1 shows the clinical and laboratory parameters during the course of the disease.
Our patient experienced complications of PH and renal insufficiency concomitantly during her second admission. PH is reported to complicate 5% of POEMS syndrome patients and is known to respond well to steroid administration. 8 Niimi et al. 9 reported that PH responded to steroid therapy with a decrease in VEGF level. The kidney is another targeted organ in POEMS syndrome. Pathological features in the kidney include membrano-proliferative glomerulonephtitis (MPGN)-like lesions. Although detailed pathogenesis still remains to be elucidated, recent studies again identified that elevated VEGF levels may be involved in the development of such renal lesions. 10 Our patient showed a comparable response in these two organs in parallel with the decrease of her VEGF levels. However, her other symptoms, such as the extravascular volume overload and polyneuropathy, did not improve with steroid therapy at all, and rather worsened, despite the reduction of VEGF levels. Although it is well established that the VEGF levels in serum samples are affected by platelet count, in our case, it was unlikely that the platelet counts had any influence on the concentration of serum VEGF, as platelet counts were almost the same, namely, 150-200 Â 10 9 /l, when the serum VEGF levels were measured.
Recently, an aggressive attempt to treat POEMS syndrome with anti-VEGF antibody has been reported. [2] [3] [4] [5] [6] Although a significant decrease in serum VEGF levels was seen in all patients, some developed multiple organ failure after bevacizumab administration, with catastrophic consequences. [3] [4] [5] The failure of bevacizumab therapy could be interpreted in two ways; one is that the therapy, simply targeting VEGF, is not sufficient to control the disease in certain patients. Another possibility is that the bevacizumab itself evoked a capillary leak, which is a well-known side effect of this antibody, instead of contributing to the improvement of POEMS syndrome. From the clinical course in our case in which the VEGF levels did not correlate with clinical symptoms, the former is more likely. It is known that cytokines other than VEGF, such as IL-1b, IL-6, and TNF-a can influence the activity of POEMS syndrome. In our case, involvement of IL-6 or TNF-a could be ruled out at least, as these cytokines were within the normal limits throughout the disease course (Table 1) .
In contrast to anti-VEGF therapy, it is generally believed that a decrease in VEGF level correlates with improvement in the clinical symptoms in POEMS syndrome patients treated with APBSCT. 7, 11 It is possible that other known or unknown cytokines may exist and play a role in the pathogenesis of POEMS syndrome, and that APBSCT, not bevacizumab, may completely normalize cytokine levels. While awaiting further studies on this subject, the efficacy and safety of bevacizumab in this syndrome should be cautiously evaluated. Dispenzieri et al. 12 reported lenalidomide to be effective for the treatment of POEMS syndrome because of its anti-VEGF effect. This new agent should be compared with APBSCT in the future. However, currently APBSCT seems to be one of the most promising strategies for the treatment of POEMS syndrome. Table 1 The clinical symptoms and laboratory data during the disease course 
